CLAIMS

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

R^1, R^2 and R^4 are independently H, halogen or C_1-C_4 alkyl;

R^3 is independently selected from phenyl and a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^a, O, and $S(O)_p$; wherein said phenyl and heteroaryl are substituted with 0-4 R^{3A};

each R^{3A} is independently selected from halogen, CN, OH, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, C(O)-C_1-C_4 alkyl, and phenyl;

each R^a is independently selected from H and C_1-C_4 alkyl; and

each p is independently selected from 0, 1 and 2.

2. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is phenyl.

3. The compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from Ph, 2-F-Ph, 3-F-Ph, 4-F-Ph, 2-Cl-Ph, 3-Cl-Ph, 4-Cl-Ph, 4-Br-Ph, 3-CF_3-Ph, 4-CF_3-Ph, 2-OMe-Ph, 3-OMe-Ph, 4-OMe-Ph, 2-OCF_3-Ph, 4-OCF_3-Ph, 2-CN-Ph, 3-CN-Ph, 4-CN-Ph, 2-C(O)Me-Ph, 1,1'-biphenyl-2-yl, 3,4-diF-Ph, 3,5-diF-Ph, 2-F-4-Cl-Ph, 3-F-4-Cl-Ph, 2-Cl-4-F-Ph, 3-Cl-4-F-Ph, 2,4-diCl-Ph, 2-CF_3-4-F-Ph, 2-CF_3-5-F-Ph, 2-CN-4-F-Ph, 2-F-3-CN-Ph, 2-F-5-CN-Ph, 2-CN-4-F-Ph, 2-OMe-4-F-Ph, 2-OMe-5-F-Ph, 2-Cl-4-OMe-Ph, 2-OMe-5-Cl-Ph, 2-OMe-4-OMe-Ph, 2-OMe-5-OMe-Ph, 3-Me-4-CF_3-Ph, 2-CF_3-4-F-Ph, 2-CF_3-4-OMe-Ph, 2-OMe-5-OCF_3-Ph, 2,4,5-triF-Ph, 2-Cl-4,5-diF-Ph, 2,6-diCl-Ph, 2-CF_3-Ph, 2-Cl-4-CF_3-Ph, 2,4-diF-Ph, and 4-ethynyl-Ph, wherein Ph represents phenyl.

4. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is pyridinyl.

5. The compound of Claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^3 is selected from pyrid-4-yl, 2-F-pyrid-3-yl, 6-F-pyrid-3-yl, 2-F-pyrid-4-yl, 3-F-pyrid-4-yl, 2-Cl-pyrid-3-yl, 2-Cl-pyrid-4-yl, 2-CF_3-pyrid-4-yl, 3-Cl-pyrid-4-yl, 3-CF_3-pyrid-4-yl, 2-CF_3-pyrid-3-yl, and 4-CF_3-pyrid-3-yl.

6. The compound of any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein

at least one of R^1, R^2 or R^3 is H.

7. The compound of Claim 1, wherein the compound is of Formula IA:



(IA)

or a pharmaceutically acceptable salt thereof.

8. The compound of Claims 1, wherein the compound is of Formula (IB):



(IB)

or a pharmaceutically acceptable salt thereof.

9. The compound of Claim 1, wherein the compound is of Formula (IC):



(IC)

or a pharmaceutically acceptable salt thereof.

10. The compound of any one of Claims 7 to 9, or a pharmaceutically acceptable salt thereof wherein R^{3A} is independently selected from –Me, –OH, -F , –Cl, -CH_2F, -CHF_2, -CF_3, –CH_2CF_3, -OMe, –OCF_3 and -O-CH_2-CF_3.

11. The compound of Claim 1 selected from:
1-(2-(5-(2-(difluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-chloro-5-(trifluoromethyl)pyridin-4-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(5-chloro-2-fluoropyridin-4-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-chloro-2-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-

oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(2-(2,2,2-trifluoroethoxy)pyridin-3-yl)isoindolin-2-yl)ethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(6-methyl-2-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(5-fluoro-2-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloro-4,6-difluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-fluoro-2-(pyrrolidin-1-yl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-fluoro-6-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-methylpyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(6-methoxy-2-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloro-3,6-difluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-fluoro-5-(trifluoromethyl)pyridin-4-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(2-(trifluoromethoxy)pyridin-3-yl)isoindolin-2-yl)ethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-chloro-2-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(2-(2,2,2-trifluoroethyl)pyridin-3-yl)isoindolin-2-yl)ethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-fluoro-2-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloro-4-fluoropyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-fluoro-4-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-chloro-5-fluoropyridin-4-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-chloro-2-fluoropyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(6-fluoro-2-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(3-(trifluoromethyl)pyridin-4-yl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(5-fluoro-2-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-fluoro-2-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloro-4,5-difluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-methoxy-2-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-cyano-4-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chlorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloro-4-methoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2,6-dichlorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(2-(trifluoromethyl)phenyl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloro-4-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-

carbonitrile; 1-(2-(5-(2,4-dichlorophenyl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-fluoro-2-(2-methoxyethoxy)phenyl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(2-(trifluoromethoxy)phenyl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(5-cyano-2-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloro-4-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-cyanophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-cyano-2-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(2,4,5-trifluorophenyl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-cyanophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-chloropyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(1-methyl-3-(trifluoromethyl)-1*H*-pyrazol-5-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-chloropyridin-4-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-acetylphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-fluoro-2-methoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile;1-(2-(5-(5-chloro-2-methoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2,4-dimethoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-cyanophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2,4-difluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(6-fluoropyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(5-fluoro-2-methoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-chloro-2-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2,5-dimethoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-fluoropyridin-4-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-methoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-methoxy-5-(trifluoromethoxy)phenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-fluoropyridin-4-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-ethynylphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(pyridin-4-yl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-bromophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-chloro-4-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-([1,1'-biphenyl]-2-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-chloro-3-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-chlorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3,4-difluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(2-fluoropyridin-3-yl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3,5-difluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-

carbonitrile; 1-(2-(5-(2-methoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(4-(trifluoromethyl)phenyl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-methoxyphenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-methyl-4-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-phenylisoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-chlorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(4-fluorophenyl)isoindolin-2-yl)-2-oxoethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(4-(trifluoromethoxy)phenyl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-(5-(3-fluoro-2-(trifluoromethyl)phenyl)isoindolin-2-yl)-2-oxoethyl)-1H-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(2-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile; 1-(2-oxo-2-(5-(4-(trifluoromethyl)pyridin-3-yl)isoindolin-2-yl)ethyl)-1*H*-1,2,4-triazole-3-carbonitrile.

12. A pharmaceutical composition comprising at least one of the compounds of any one of Claims 1 to 11 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient.

13. The pharmaceutical composition of Claim 12 further comprising additional therapeutic agent(s).

14. A compound of any one of Claims 1 to 11 for use in therapy, alone, or optionally in combination with another compound of any one of Claims 1 to 11, and/or at least one other type of therapeutic agent.

15. Use of a compound of any one of Claims 1 to 11 or optionally in combination with another compound of the present invention and/or at least one other type of therapeutic agent in the manufacture of a medicament for the treatment of the pathology and/or symptomology of a disease caused by a parasite, alone.

16. Use of a compound of any one of Claims 1 to 11 in the manufacture of a medicament for the treatment of the pathology and/or symptomology of a disease caused by a parasite, in combination with an additional therapeutic agent(s) to form a combined preparation, for simultaneous, separate or sequential use.

17. The use of Claim 15 or Claim 16, wherein the disease is selected from leishmaniasis, human African trypanosomiasis and Chagas disease.

18. The use of Claim 15 or Claim 16, wherein the additional therapeutic agent(s) used are selected from, for treating leishmaniasis, meglumine antimoniate, stibogluconate, Amphotericin, Miltefosine and paromomycin; for treating human African trypanosomiasis, pentamidine, suramin, melarsoprol, eflornithine, fexinidazole and SCYX-7158; and for treating Chagas disease, benznidazole, nifurtimox and Amphotericin b, and the pharmaceutical composition of Claim 13, wherein the additional therapeutic agent(s) used are selected from, meglumine antimoniate, stibogluconate, Amphotericin, Miltefosine and paromomycin, pentamidine, suramin, melarsoprol, eflornithine, fexinidazole and SCYX-7158, benznidazole, nifurtimox and Amphotericin b.